



Level 2, 517 Flinders Lane
Melbourne, Australia 3000

ACN: 123 055 363
website: www.patrys.com

ASX & Media Release

Melbourne, 31 January 2008

Patrys Announces Commencement of Scale-Up Manufacturing of Lead Product PAT-LM1

After an extensive review of proposals from leading contract manufacturing firms, Patrys Limited (ASX: PAB) has appointed U.S. based AppTec Laboratory Services to manufacture PAT-LM1 for preclinical and clinical purposes. PAT-LM1, one of the Company's lead products, is a natural human antibody that is being developed by Patrys for the treatment of cancer.

The program for PAT-LM1 at AppTec has already commenced, allowing Patrys to remain on track in its preclinical and clinical development plan for this lead anti-cancer antibody.

"AppTec has extensive antibody production experience, and offers Patrys a flexible and single source for antibody testing and clinical and in-market production under regulatory established guidelines," stated Mike Conner, Patrys Vice President, Manufacturing. "The Patrys management team is confident that AppTec will deploy those resources effectively to make the clinical production of PAT-LM1 a success."

"We are pleased that Patrys has entrusted AppTec with the production of PAT-LM1, and our early work with the Patrys team and their technology gives us great confidence in the success of this program," stated Larry Thomas, AppTec's Executive VP, Biotech Business Development. "More broadly, AppTec is excited about being able to deploy our considerable expertise and capabilities to bringing this promising anti-cancer human antibody to patients."

Acceptys Announces Anti-Malaria Antibody Program

Patrys affiliated company, Acceptys, Inc., has announced a collaboration with the Seattle Biomedical Research Institute, focused on the discovery and development of anti-malaria natural human antibodies and vaccines. For more information, please see <http://www.patrys.com/mediareleases.php>.

For more information:

Dr. Vic Ilag
Chief Operating Officer, Patrys Limited
M: +61 400 861 747 or info@patrys.com

Kris Blader
President, Acceptys, Inc.
U.S. Phone: 973-729-7779

Larry Thomas
Executive VP, Biotech Business Development
AppTec
651-675-2047 or 888-794-0077 Ext.2047

About Patrys Limited:

Based in Melbourne, Australia, Patrys is a publicly traded company (ASX: PAB) focused on the commercialisation of its proprietary platform technologies for the capture, production, and development of natural human antibodies as therapies for cancer and other diseases. Patrys has a deep pipeline of IgM and IgG form anti-cancer natural human antibodies, 12 of which have progressed to lead status. Patrys' main objective is to initiate and complete first-in-human clinical trials for its two most advanced lead products, PAT-LM1 and PAT-SM6. Patrys also has collaborations with several larger pharmaceutical companies to advance additional anti-cancer products from its pipeline. The Company has operations in Australia, Germany and the USA. For further details on Patrys please refer www.patrys.com.

About Acceptys, Inc.:

Acceptys is a biotechnology company focused on the commercialization of its proprietary platform technologies for the capture, production and development of natural human antibodies as therapies for infectious disease. Acceptys has a number of programs in progress, including natural

For personal use only

human antibody programs focused on pneumonia, Hepatitis C and malaria. Acceptys is affiliated with Patrys Limited (ASX: PAB), an Australia publicly listed company focused on the development of natural human antibodies for cancer and other major indications. www.patrys.com. For more information about Acceptys, visit www.acceptys.com.

About AppTec:

With over 20 years experience, AppTec is a trusted leader in providing high-value testing, contract R&D, and cGMP manufacturing services for the biopharmaceutical and medical device industries. AppTec offers a fully integrated approach for the development of highly regulated products such as biopharmaceuticals, traditional pharmaceuticals, cellular therapeutics, medical devices, and combination and tissue-based products. Possessing the full set of competencies, facilities, and key personnel necessary, AppTec helps clients take their products efficiently and cost-effectively through the product development process. The company has three state-of-the art facilities, which are located in St. Paul, MN; Philadelphia, PA; and Atlanta, GA. All AppTec facilities are FDA registered and GLP/GMP compliant.